Amanote Research
Register
Sign In
Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin
Clinical Medicine Reviews in Women's Health
doi 10.4137/cmrwh.s5235
Full Text
Open PDF
Abstract
Available in
full text
Date
January 1, 2010
Authors
Unknown
Publisher
Portico
Related search
A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer
Health Technology Assessment
Medicine
Health Policy
A Retrospective Analysis of Pegylated Liposomal Doxorubicin in Ovarian Cancer: Do We Still Need It?
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial
Oncology Letters
Cancer Research
Oncology
Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy
OnCOReview
Oncology
Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
PLoS ONE
Multidisciplinary
Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas
Haematologica
Hematology
Modeling Pegylated Liposomal Doxorubicin-Induced Hand-Foot Syndrome and Intestinal Mucositis in Zebrafish
OncoTargets and Therapy
Oncology
Pharmacology
Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?
Oncologist
Cancer Research
Medicine
Oncology
Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)
Scientific Reports
Multidisciplinary
